Financial Comparison: Mallinckrodt PLC (MNK) vs. Repligen Corporation (RGEN)
Mallinckrodt PLC (NYSE: MNK) and Repligen Corporation (NASDAQ:RGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Earnings and Valuation
This table compares Mallinckrodt PLC and Repligen Corporation’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mallinckrodt PLC||$3.27 billion||1.08||$666.60 million||$4.10||8.70|
|Repligen Corporation||$113.32 million||12.50||$29.54 million||$0.51||74.35|
Mallinckrodt PLC has higher revenue and earnings than Repligen Corporation. Mallinckrodt PLC is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Mallinckrodt PLC has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Mallinckrodt PLC and Repligen Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mallinckrodt PLC presently has a consensus price target of $59.97, suggesting a potential upside of 68.03%. Repligen Corporation has a consensus price target of $46.00, suggesting a potential upside of 21.31%. Given Mallinckrodt PLC’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Mallinckrodt PLC is more favorable than Repligen Corporation.
Institutional and Insider Ownership
97.4% of Mallinckrodt PLC shares are owned by institutional investors. Comparatively, 97.9% of Repligen Corporation shares are owned by institutional investors. 0.8% of Mallinckrodt PLC shares are owned by company insiders. Comparatively, 1.5% of Repligen Corporation shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Mallinckrodt PLC and Repligen Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Mallinckrodt PLC beats Repligen Corporation on 8 of the 14 factors compared between the two stocks.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.